COMMUNITY CLINICAL ONCOLOGY PROGRAM-NSABP RESEARCH BASE

这项建议的主要目的是继续发挥 国家外科辅助乳肠项目(NSABP)作为一项 NCI-社区临床肿瘤学项目指定研究基地 (CCOP)。具体地说，NSABP将：提供乳房和结直肠 临床治疗方案和癌症控制研究方案 参与CCOP的医生；提供支持服务和教育 针对CCOP相关员工的计划；通过持续的 质量保证计划；继续成功整合CCOP 调查人员对NSABP的整体运作进行调查。 自1983年以来，作为CCOP研究基地，NSABP拥有更多的CCOP从属关系 比任何其他临床协作组都要好。由于他们的 合作，NSABP约占所有CCOP的20% 临床试验治疗收益和约15%的所有受试者 在过去的三年里参加了癌症控制研究。在 NSABP，CCOP目前贡献了所有佐剂研究收益的30%。 通过保持CCOP医生在NSABP中的广泛参与 研究：1)参与临床试验的好处将继续 在社区环境中更广泛地使用，其中超过80%的 癌症患者得到治疗；2)对治疗问题的回答 正在研究中的协议将更快地推出；以及3)更广泛的细分市场 将可用于研究和衡量进步 在癌症控制方面。

The primary aim of this proposal is to continue the active role that the National Surgical Adjuvant Breast and Bowel Project (NSABP) has had as an NCI-designated research base for the Community Clinical Oncology Project (CCOP). Specifically, the NSABP will: provide breast and colorectal clinical treatment protocols and cancer control research protocols for participating CCOP physicians; provide support services and educational programs for CCOP-related staff; monitor CCOP performance through ongoing quality assurance programs; continue the successful integration of CCOP investigators into the overall functioning of the NSABP. As a CCOP research base since 1983, the NSABP has more CCOP affiliations than any other clinical cooperative group. As a result of their collaboration, the NSABP has accounted for approximately 20% of all CCOP clinical trial treatment accrual and approximately 15% of all subjects entered on cancer control studies over the past three years. Within the NSABP, CCOPs are currently contributing 30% of all adjuvant study accrual. By maintaining this expanded involvement of CCOP physicians in NSABP studies: 1) the benefits of clinical trial participation will continue to be more widely available in the community setting, where over 80% of all cancer patients are treated; 2) answers to the therapeutic questions posed in study protocols will be available more quickly; and 3) a wider segment of the community will be available for research and measurement of advances in cancer control.